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BRIEF REPORT
The Value of a Patient Global Assessment of Disease Activity in Granulomatosis
With Polyangiitis (Wegener’s)
Gunnar Tomasson,1 John C. Davis,2 Gary S. Hoffman,3 W. Joseph McCune,4 Ulrich Specks,5 Robert Spiera,6
E. William St.Clair,7 John H. Stone,8 and Peter A. Merkel9
Objective. To 1) describe the distribution of pa-
tient global assessment (PtGA) scores of disease activity
in patients with granulomatosis with polyangiitis (GPA;
Wegener’s), 2) explore the discordance between PtGA
scores and physician global assessment (PhGA) scores
of disease activity, and 3) explore whether PtGA scores
during disease remission are associated with future
disease relapse.
Methods. Data from the Wegener’s Granulomato-
sis Etanercept Trial (WGET) were used. PtGA and
PhGA scores were assessed on 100-mm visual analog
scales (VAS). Presence of active disease was determined
using the Birmingham Vasculitis Activity Score for WG
(BVAS/WG), and remission was defined as a BVAS/WG
score of 0. Disease relapse was defined as a BVAS/WG
score of >0 after remission had been achieved. Discor-
dance between PtGA and PhGA scores was defined as a
difference of >20 points between the two measures.
Mixed linear models were used in longitudinal analysis
of PtGA scores.
Results. Data were obtained from 180 patients in
the WGET cohort, seen at a total of 1,719 study visits.
The mean  SD PtGA and PhGA disease activity scores
(on 100-mm VAS) at baseline were 64.2  27.4 and
55.5  23.4, respectively. PtGA–PhGA discordance oc-
curred in 53% of patients at baseline, and this was
inversely associated with newly diagnosed disease (as
opposed to relapsing disease) at baseline (odds ratio
0.37, 95% confidence interval [95% CI] 0.20–0.68) but
not with age, sex, or presence of renal or pulmonary
disease. Patients were in disease remission during 62%
of the study visits. The mean PtGA score during visits
immediately prior to relapse was 4.52 points higher
(95% CI 0.66–8.4) than that at other remission visits
(P  0.03).
Conclusion. PtGA–PhGA discordance is common
in GPA. A rise in the PtGA disease activity score during
times defined by physicians as periods of remission is
associated with subsequent occurrence of disease re-
lapse. These findings support the addition of PtGA as
an outcome measure for GPA.
Granulomatosis with polyangiitis (GPA; Wegen-
er’s) is a multisystem disease that often has a chronic
course with frequent periods of relapse and remission.
Disease remission is attained for the great majority of
patients, and longitudinal studies demonstrate that pa-
tients with GPA are in apparent remission at most study
visits (1–4). The Birmingham Vasculitis Activity Score
(BVAS) (5) and its modifications are the most widely
accepted tools for disease activity assessment in antineu-
trophil cytoplasmic antibody–associated vasculitis, with
remission usually defined as a BVAS score of 0. How-
ever, the BVAS is a purely physician-based disease
measure that relies on the physician’s judgment regard-
ing involvement of individual organ systems and attribu-
tion of manifestations to disease activity but not to
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permanent damage, adverse effects from treatments, or
other nonvasculitis disease processes. It is increasingly
recognized that patients can provide insight to disease
assessment beyond what can be obtained from
physician-based disease assessments or laboratory values
(6–8).
The objectives of this study were to 1) describe
the distribution of scores for patient global assessment
(PtGA) of disease activity in patients with GPA enrolled
in a clinical trial, 2) explore the discordance between
PtGA scores and physician global assessment (PhGA)
scores of disease activity, and 3) explore whether PtGA
scores during disease remission are associated with
future occurrence of disease relapse.
PATIENTS AND METHODS
Data source. Data from the Wegener’s Granulomato-
sis Etanercept Trial (WGET) (1) (see Appendix A for a list of
participating centers and investigators) were used. The WGET
was a randomized, double-blind, placebo-controlled trial con-
ducted at 8 clinical centers in North America, testing the
addition of etanercept or placebo to standard remission-
induction therapy (glucocorticoids plus cyclophosphamide or
methotrexate) for patients with GPA. Patients were enrolled at
a time of active vasculitis and had study visits at baseline, 6
weeks, and every 3 months thereafter.
Study variables. PtGA scores of disease activity were
assessed at every study visit, on a 100-mm visual analog scale
(VAS) (scored 0–100), with the question, “Please mark the line
below indicating how active you believe your Wegener’s gran-
ulomatosis has been in the past 28 days. Consider only how
much your Wegener’s (the disease itself) is causing you
problems. Do not count the effects of other medical problems
or side effects of medications.” PhGA scores of disease activity
were assessed at every study visit, on a 100-mm VAS (scored
0–100), with the question, “Mark line to indicate the amount of
WG disease activity (not including longstanding damage)
within the previous 28 days.”
Disease activity was assessed with the BVAS/WG (9).
The BVAS/WG measures activity in 34 items, categorized into
9 groups. BVAS/WG values range from 0 to 63, with higher
scores representing more manifestations of active disease.
Active disease was defined as a BVAS/WG score of 0, and
remission was defined as a BVAS score of 0. Disease relapse
was defined as a BVAS/WG score of 0 when the BVAS/WG
score had been 0 at the preceding study visit.
Renal disease and pulmonary disease were each de-
fined on the basis of corresponding BVAS/WG items. Health-
related quality of life (HRQOL) was assessed with the Short
Form 36 (SF-36) health survey at the baseline visit. The SF-36
contains 36 items that assess HRQOL in 8 health dimensions:
physical functioning, role physical, bodily pain, general health,
vitality, social functioning, role emotional, and mental health
(10,11). Scores for each dimension/subscale range from 0 to
100, with higher scores indicating better HRQOL. Two sum-
mary scores are derived from the 8 subscales: the physical
component summary score and the mental component sum-
mary score, both of which are norm-based scores standardized
to the values for the US general population and transformed to
have a mean of 50 and SD of 10 in the referent population.
PtGA–PhGA discordance was defined as a difference
between the PtGA and PhGA scores (on 100-mm VAS) of
20 points. We also explored whether our findings were
sensitive to discordance thresholds of 10 points or 30
points.
Statistical analysis. The distribution of outcome mea-
sures at baseline was expressed as the mean  SD. Pearson’s
correlation coefficients were calculated to determine the cor-
relations between the global assessment scores and the SF-36
subscores. Logistic regression was used to explore the associ-
ation of PtGA–PhGA discordance with age, sex, newly diag-
nosed disease or relapsing disease at baseline, and presence of
renal or pulmonary disease. The association of the demo-
graphic and disease-associated factors with PtGA–PhGA dis-
cordance was expressed as the odds ratio (OR) with 95%
confidence intervals (95% CIs).
To explore whether the PtGA score was increased
prior to overt disease relapse, analysis was limited to data from
visits during remission. Mixed linear models were used to
explore differences in PtGA scores between study visits during
remission but immediately prior to overt relapse, and other
study visits during remission; random intercepts were included
in the models to account for multiple observations from each
subject. The difference in PtGA scores at visits prior to relapse
compared to other remission visits was expressed as points on
the VAS with 95% CIs. All statistical analyses were done using
SAS version 9.2.
RESULTS
Patients. One-hundred eighty patients partici-
pated in the WGET and were seen at a total of 1,719
study visits. At baseline, when all patients had active
disease (mean  SD BVAS/WG score 7.0  3.4), the
mean  SD PtGA score was 64.2  27.4, and the
mean SD PhGA score was 55.5 23.4. At study entry,
100 patients had relapsing disease and 80 patients had a
new diagnosis of GPA. Renal involvement was present
at baseline in 97 patients (54%), and pulmonary involve-
ment was present at baseline in 108 patients (60%).
Correlations of measures at baseline. PtGA
scores were modestly correlated with both PhGA scores
(r  0.30, P  0.0001) and BVAS/WG scores (r  0.28,
P  0.0001). PhGA scores were highly correlated with
BVAS/WG scores (r  0.62, P  0.0001). The PtGA
score correlated weakly or moderately with all of the
subscores of the SF-36; no correlation or much weaker
correlations were observed between the PhGA score and
SF-36 subscores (Table 1).
Discordance between patient and physician
global assessments at baseline. At baseline, there was
substantial discordance regarding the assessment of dis-
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ease activity between the patients and the physicians.
For 95 patients (53%), there was a difference of at least
20 points between the PtGA and PhGA scores. Having
newly diagnosed disease at study entry was inversely
associated with PtGA–PhGA discordance (OR 0.37,
95% CI 0.20–0.68). This means that patients with newly
diagnosed disease were more likely than those with
relapsing disease to agree with the physician’s global
assessment of disease activity. This inverse association
was not dependent on the defined threshold for PtGA–
PhGA discordance (Table 2). No demographic or
disease-related factor was significantly associated with
the PtGA–PhGA discordance.
Patient global assessment during remission and
its association with future disease relapse. Of the 180
patients with GPA, 162 (90%) achieved disease remis-
sion (BVAS/WG score of 0) on at least one study visit.
Among these 162 patients, 74 (46%) experienced at least
one disease relapse. The 162 patients who achieved
remission had a total of 1,058 visits during the times of
remission, of which 103 visits were followed by a disease
relapse. At visits immediately prior to relapse, the mean
PtGA score was 4.52 points higher (95% CI 0.66–8.4)
compared to that at other remission visits (P  0.03)
(Table 3). Among the 74 patients who experienced
disease relapse after achievement of remission, the
PtGA score was 3.0 points higher (95% CI 1.68–7.76)
at the visit immediately preceding relapse compared to
that at other remission visits among this group (P 
0.21).
DISCUSSION
This study demonstrates that a simple patient-
reported outcome, in this case a global score of disease
activity measured by a 100-mm VAS, captures novel and
important disease aspects in GPA. The PtGA only
modestly correlates with other outcome measures, and
patient and physician disease assessments were com-
monly discordant. Correlations between subscores of the
SF-36 and the PtGA score were weak or modest, but
statistically significant. These findings support several
intriguing concepts: 1) the PtGA captures disease do-
mains not assessed by physician-based measures; 2)
Table 1. Correlations of the patient and physician global assessment
scores of disease activity with subscores of the SF-36*
Patient global
assessment
Physician global
assessment
SF-36 domain Pearson’s r P Pearson’s r P
Pain 0.36 0.0001 0.09 0.250
Physical function 0.31 0.0001 0.21 0.0039
Role physical 0.33 0.0001 0.10 0.16
Role emotional 0.23 0.0023 0.13 0.08
Social function 0.45 0.0001 0.20 0.0064
Vitality 0.42 0.0001 0.13 0.0788
General health 0.30 0.0001 0.00 0.98
Mental health 0.27 0.0003 0.08 0.26
PCS 0.38 0.0001 0.13 0.08
MCS 0.30 0.0001 0.12 0.11
* Correlations of the 36-item Short Form (SF-36) subscores with
patient and physician global assessment scores on 100-mm visual
analog scales were determined using Pearson’s correlation coefficients.
PCS  physical component summary score; MCS  mental compo-
nent summary score.
Table 2. Associations of demographic and disease factors with discordance between the patient and
physician global assessments of disease activity*
Variable
10-point
discordance
(n  131)
20-point
discordance
(n  95)
30-point
discordance
(n  65)
Age (per 1 year) 1.00 (0.98–1.03) 1.00 (0.99–1.02) 1.00 (0.99–1.03)
Male sex 2.37 (1.20–4.67) 1.44 (0.79–2.64) 0.99 (0.53–1.85)
Newly diagnosed disease (at baseline) 0.57 (0.30–1.11) 0.37 (0.20–0.68) 0.32 (0.16–0.61)
Renal disease 1.17 (0.60–2.28) 0.68 (0.38–1.23) 0.61 (0.33–1.13)
Pulmonary disease 0.91 (0.46–1.81) 0.90 (0.49–1.65) 0.81 (0.44–1.51)
* Discordance was defined as a 10-, 20-, or 30-point minimum difference between patient global
assessment and physician global assessment scores. Values are the odds ratio (95% confidence interval).
Table 3. Patient global assessment scores during times of remission
and disease relapse*
Score P†
Remission (n  885)‡ 15.7 Referent
Two visits prior to relapse (n  70) 17.7 0.41
One visit prior to relapse (n  103) 20.2 0.03
Relapse visit (n  103) 28.2 0.001
* Values are the mean patient global assessment scores (n  number
of study visits) during remission, at visits leading up to disease relapse,
and at visits after disease relapse.
† Versus the referent group.
‡ Remission that is not followed by a relapse during the next 2 study
visits.
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change in a patient-reported outcome (PtGA) during
remission precedes periods of active disease as detected
by physicians; and 3) in GPA, there may be periods of
occult disease activity that are not captured by the
current standard of physician-based activity measures
(BVAS, PhGA).
The finding that, when compared to patients in
the WGET trial with relapsing disease at baseline,
patients with newly diagnosed GPA at the baseline visit
were more likely to agree with their physician with
respect to assessment of disease activity was unexpected.
It is possible that disease assessment in cases of relapsing
disease presents more complexities than that in newly
presented cases, with a need by both physicians and
patients to differentiate active disease from the effects of
disease- or treatment-related damage.
This study has important strengths. The data
source was a well-defined patient cohort with GPA,
characterized by high disease activity at baseline, fol-
lowed by disease remission in a majority of the patients,
and then by 1 or more relapses in a substantial number
of patients. The assessments were made prospectively
per a clearly defined protocol at centers expert in the
care of patients with GPA. The dynamics of disease
trajectories seen in this cohort and comprehensive,
repeated standardized disease assessments make this a
rich data source for assessing the utility of outcome
measures in GPA.
The study also has some limitations. Direct mea-
sures of fatigue, pain, dyspnea, and other important
manifestations of disease from the patient perspective
(12) were not collected. Although the observed mea-
sures of correlation between subscores of the SF-36 and
the PtGA score suggest that fatigue (vitality) and social
function might be the domains of HRQOL that contrib-
ute the most to the PtGA, individual subscores of the
SF-36 did not have optimal distribution for such calcu-
lations, and therefore these results should be interpreted
with caution. Further exploration of the dimensions of
disease captured by the PtGA is much needed. Based on
findings from the WGET, etanercept is generally con-
sidered inefficacious for the treatment of GPA. There-
fore, data originating from the WGET would not allow
assessment of how outcome measures discriminate be-
tween treatment arms. Consistent with the trial’s pri-
mary conclusion, PtGA scores did not discriminate
between treatment arms in this study (results not
shown).
The utility of the PtGA should be explored
further with respect to its construct validity with other
disease manifestations and its ability to discriminate
between treatment arms. It is likely that the PtGA could
contribute to a composite measure of disease activity in
GPA, as it has for other diseases (13,14), and could
provide unique information complementary to standard
physician assessments. In the absence of tools better
than those currently available for assessment of disease
activity in GPA, data obtained through the use of this
highly feasible patient-reported outcome should be col-
lected in all longitudinal studies of GPA, especially in
randomized controlled trials of therapies in GPA.
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